<DOC>
	<DOCNO>NCT02709512</DOCNO>
	<brief_summary>This study ADI-PEG 20 ( pegylated arginine deiminase ) , arginine degrade enzyme versus placebo patient malignant pleural mesothelioma low argininosuccinate synthetase 1 expression . Malignant pleural mesothelioma find require arginine , amino acid . Thus hypothesis restrict arginine ADI-PEG 20 , malignant pleural mesothelioma cell starve die .</brief_summary>
	<brief_title>Ph 2/3 Study Subjects With MPM w/Low ASS 1 Expression Assess ADI-PEG 20 With Pemetrexed Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically proven advance MPM biphasic sarcomatoid histology . Biphasic MPM define use World Health Organization 's international histological classification tumor contain epithelial sarcomatoid component component comprise least 10 % tumor 2 . Na√Øve prior chemotherapy immunotherapy ( i.e. , firstline systemic therapy study ) . 3 . MPM tumor sample determination ASS1 status . ASS1deficiency require study entry study start , tumor sample ASS1 status require . This study employ adaptive biomarkerdriven design interim analysis conduct end phase 2 portion . The interim analysis evaluate treatment effect ADI PEG 20 combination pemetrexed cisplatin overall survival ( OS ) overall population ( biphasic sarcomatoid histology patient ) predefined subpopulation biomarkerpositive patient ( ASS1deficient subpopulation ) . Thus ASS1 deficiency may require phase 3 portion study , pending interim analysis . ASS1deficiency , demonstrate tissue specimen ( cytospin sample acceptable ) , define laboratory manual . If archive tissue sufficient available , tissue must obtain biopsy . 4 . Measurable disease assess modified RECIST MPM thoracic disease ( Appendix A ) RECIST 1.1 extrathoracic disease ( Appendix B ) . 5 . ECOG performance status 0 1 ( Appendix C ) . 6 . Predicted life expectancy least 12 week . 1 . Radiotherapy ( except palliative reason ) previous two week . 2 . Ongoing toxic manifestation previous treatment . 3 . Symptomatic brain spinal cord metastasis ( patient must stable &gt; 1 month post radiotherapy surgery ) . 4 . Major thoracic abdominal surgery patient yet recover . 5 . Serious infection require treatment intravenous antibiotic time study entrance , infection require intravenous therapy within 7 day prior . 6 . Known serologically positive human immunodeficiency virus ( HIV ) . Testing determine possible infection status require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Malignant Pleural Mesothelioma Low Argininosuccinate Synthetase 1 Expression</keyword>
</DOC>